Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026)

Neurocrine Biosciences has reported Research & Development for 17 years, with the latest figure at $296.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 12.54% year-over-year to $296.2 million; the trailing twelve-month figure through Mar 2026 stood at $819.4 million (up 25.81% YoY), and the FY2025 full-year result was $1.0 billion, up 38.93% from the prior year.
• Research & Development for Q1 2026 stood at $296.2 million, up from $258.2 million in the prior quarter.
• The five-year high for Research & Development was $296.2 million in Q1 2026, with the low at $5.0 million in Q1 2024.
• Historically, Research & Development has averaged $135.5 million across 5 years, with a median of $139.5 million in 2023.
• Annual changes were most pronounced in 2024 — Research & Development slumped 96.42% — and 2025, when it soared 5164.0%.
• Neurocrine Biosciences' Research & Development stood at $118.0 million in 2022, then increased by 16.53% to $137.5 million in 2023, then soared by 34.98% to $185.6 million in 2024, then soared by 39.12% to $258.2 million in 2025, then grew by 14.72% to $296.2 million in 2026.
• The last three Research & Development figures came in at $296.2 million (Q1 2026), $258.2 million (Q4 2025), and $250.0 million (Q3 2025), per Business Quant data.